Total Payments
$4,994
2024 Payments
$581.87
Companies
33
Transactions
187
Medicare Patients
1,276
Medicare Billing
$421,436
Payment Breakdown by Category
Food & Beverage$4,054 (81.2%)
Research$940.27 (18.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Food and Beverage | $4,054 | 177 | 81.2% |
| Unspecified | $940.27 | 10 | 18.8% |
Payments by Type
General
$4,054
177 transactions
Research
$940.27
10 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Gilead Sciences, Inc. | $940.27 | 10 | $0 (2019) |
| AstraZeneca Pharmaceuticals LP | $572.92 | 30 | $0 (2024) |
| Bayer Healthcare Pharmaceuticals Inc. | $426.08 | 17 | $0 (2024) |
| Vifor Pharma, Inc. | $408.68 | 23 | $0 (2023) |
| OPKO Pharmaceuticals, LLC | $360.69 | 18 | $0 (2024) |
| Mallinckrodt Hospital Products Inc. | $318.80 | 12 | $0 (2024) |
| Travere Therapeutics, Inc. | $216.14 | 5 | $0 (2024) |
| Otsuka America Pharmaceutical, Inc. | $201.85 | 9 | $0 (2024) |
| Mallinckrodt Enterprises LLC | $181.66 | 4 | $0 (2019) |
| Amgen Inc. | $124.60 | 4 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $581.87 | 24 | Mallinckrodt Hospital Products Inc. ($143.83) |
| 2023 | $1,006 | 36 | Travere Therapeutics, Inc. ($182.62) |
| 2022 | $798.20 | 42 | AstraZeneca Pharmaceuticals LP ($160.83) |
| 2021 | $646.77 | 30 | Bayer HealthCare Pharmaceuticals Inc. ($189.28) |
| 2020 | $419.90 | 18 | OPKO Pharmaceuticals, LLC ($109.94) |
| 2019 | $1,346 | 26 | Gilead Sciences, Inc. ($940.27) |
| 2018 | $174.86 | 10 | Keryx Biopharmaceuticals, Inc. ($56.45) |
| 2017 | $20.96 | 1 | BAXTER HEALTHCARE ($20.96) |
All Payment Transactions
187 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/06/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $20.78 | General |
| Category: NEPHROLOGY | ||||||
| 11/14/2024 | Otsuka America Pharmaceutical, Inc. | JYNARQUE (Drug) | Food and Beverage | In-kind items and services | $25.13 | General |
| Category: NEPHROLOGY | ||||||
| 11/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $25.83 | General |
| Category: IMMUNOLOGY | ||||||
| 11/01/2024 | AKEBIA THERAPEUTICS INC | Vafseo (Drug) | Food and Beverage | In-kind items and services | $24.56 | General |
| Category: Nephrology | ||||||
| 10/18/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $18.74 | General |
| Category: NEPHROLOGY | ||||||
| 10/11/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $26.13 | General |
| Category: DIABETES | ||||||
| 10/04/2024 | Bayer Healthcare Pharmaceuticals Inc. | Kerendia (Drug) | Food and Beverage | In-kind items and services | $26.92 | General |
| Category: Cardio-renal | ||||||
| 09/06/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $13.37 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/28/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $20.76 | General |
| Category: NEPHROLOGY | ||||||
| 08/23/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $13.12 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 08/09/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $35.20 | General |
| Category: IMMUNOLOGY | ||||||
| 06/28/2024 | ANI Pharmaceuticals, Inc. | PURIFIED CORTROPHIN GEL (Drug) | Food and Beverage | In-kind items and services | $16.46 | General |
| Category: Treatment of certain chronic autoimmune disorders including acute exacerbations of MS and RA | ||||||
| 06/25/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $25.25 | General |
| Category: IMMUNOLOGY | ||||||
| 06/21/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $15.07 | General |
| Category: NEPHROLOGY | ||||||
| 06/13/2024 | Ardelyx, Inc. | IBSRELA (Drug) | Food and Beverage | In-kind items and services | $25.48 | General |
| Category: GASTROENTEROLOGY | ||||||
| 05/31/2024 | AstraZeneca Pharmaceuticals LP | FARXIGA (Drug) | Food and Beverage | In-kind items and services | $29.86 | General |
| Category: Cardiovascular and Metabolism | ||||||
| 04/19/2024 | Lexicon Pharmaceuticals, Inc. | — | Food and Beverage | In-kind items and services | $18.61 | General |
| 04/10/2024 | JAZZ PHARMACEUTICALS INC. | XYWAV (Drug) | Food and Beverage | In-kind items and services | $18.39 | General |
| Category: NEUROLOGY | ||||||
| 03/29/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $30.44 | General |
| Category: IMMUNOLOGY | ||||||
| 03/15/2024 | Boehringer Ingelheim Pharmaceuticals, Inc. | JARDIANCE (Drug) | Food and Beverage | In-kind items and services | $32.67 | General |
| Category: DIABETES | ||||||
| 02/23/2024 | OPKO Pharmaceuticals, LLC | RAYALDEE (Drug) | Food and Beverage | In-kind items and services | $22.28 | General |
| Category: NEPHROLOGY | ||||||
| 02/09/2024 | Novartis Pharmaceuticals Corporation | — | Food and Beverage | In-kind items and services | $36.19 | General |
| 02/02/2024 | Travere Therapeutics, Inc. | — | Food and Beverage | In-kind items and services | $33.52 | General |
| 01/19/2024 | Mallinckrodt Hospital Products Inc. | ACTHAR (Biological) | Food and Beverage | In-kind items and services | $27.11 | General |
| Category: IMMUNOLOGY | ||||||
| 12/01/2023 | Lexicon Pharmaceuticals, Inc. | Inpefa (Drug) | Food and Beverage | In-kind items and services | $16.76 | General |
| Category: Inhibitor of SGLT2 and SGLT1 | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Study Evaluating the Efficacy and Safety of Selonsertib in Subjects with Moderate to Advanced Diabetic Kidney Disease | Gilead Sciences, Inc. | $940.27 | 10 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 7 | 315 | 897 | $213,441 | $93,918 |
| 2022 | 8 | 320 | 1,054 | $256,270 | $107,918 |
| 2021 | 8 | 348 | 1,272 | $336,910 | $136,223 |
| 2020 | 8 | 293 | 812 | $248,533 | $83,378 |
Total Patients
1,276
Total Services
4,035
Medicare Billing
$421,436
Procedure Codes
31
All Medicare Procedures & Services
31 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2023 | 27 | 138 | $100,188 | $38,493 | 38.4% |
| 99232 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes | Facility | 2023 | 92 | 390 | $54,210 | $24,086 | 44.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 83 | 181 | $22,625 | $12,338 | 54.5% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 46 | 114 | $19,038 | $10,592 | 55.6% |
| 99222 | Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes | Facility | 2023 | 32 | 39 | $8,307 | $3,956 | 47.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 17 | 17 | $4,879 | $2,302 | 47.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 18 | 18 | $4,194 | $2,150 | 51.3% |
| 90960 | Dialysis services, 4 or more physician visits per month (20 years or older) | Office | 2022 | 21 | 175 | $127,050 | $50,152 | 39.5% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 98 | 530 | $73,670 | $29,454 | 40.0% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 89 | 199 | $24,875 | $13,468 | 54.1% |
| 99222 | Initial hospital inpatient care per day, typically 50 minutes | Facility | 2022 | 44 | 51 | $10,863 | $5,368 | 49.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 22 | 47 | $7,849 | $3,740 | 47.7% |
| 99223 | Initial hospital inpatient care per day, typically 70 minutes | Facility | 2022 | 17 | 17 | $4,879 | $2,496 | 51.2% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 18 | 18 | $4,194 | $2,213 | 52.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 17 | $2,890 | $1,027 | 35.5% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2021 | 31 | 227 | $185,856 | $66,222 | 35.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 112 | 684 | $95,076 | $39,315 | 41.4% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Office | 2021 | 92 | 230 | $28,750 | $16,462 | 57.3% |
| 99222 | Initial hospital inpatient care, typically 50 minutes per day | Facility | 2021 | 40 | 44 | $9,372 | $4,701 | 50.2% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 26 | 37 | $6,179 | $3,061 | 49.5% |
| 99223 | Initial hospital inpatient care, typically 70 minutes per day | Facility | 2021 | 18 | 18 | $5,166 | $2,768 | 53.6% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Office | 2021 | 17 | 17 | $3,961 | $2,290 | 57.8% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 12 | 15 | $2,550 | $1,403 | 55.0% |
| 90960 | Dialysis services (4 or more physician visits per month), patient 20 years of age and older | Office | 2020 | 40 | 194 | $161,898 | $45,146 | 27.9% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 78 | 286 | $35,889 | $16,371 | 45.6% |
About Dr. Gopal Doshi, MD
Dr. Gopal Doshi, MD is a Specialist healthcare provider based in Arlington, Texas. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 08/10/2005. The National Provider Identifier (NPI) number assigned to this provider is 1619978772.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Gopal Doshi, MD has received a total of $4,994 in payments from pharmaceutical and medical device companies, with $581.87 received in 2024. These payments were reported across 187 transactions from 33 companies. The most common payment nature is "Food and Beverage" ($4,054).
As a Medicare-enrolled provider, Doshi has provided services to 1,276 Medicare beneficiaries, totaling 4,035 services with total Medicare billing of $421,436. Data is available for 4 years (2020–2023), covering 31 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Other Specialties Nephrology, Internal Medicine
- Location Arlington, TX
- Active Since 08/10/2005
- Last Updated 06/28/2017
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1619978772
Products in Payments
- LOKELMA (Drug) $503.23
- ACTHAR (Biological) $500.46
- Veltassa (Drug) $430.42
- Kerendia (Drug) $426.08
- RAYALDEE (Drug) $360.69
- JYNARQUE (Drug) $201.85
- TARPEYO (Drug) $109.01
- OXLUMO (Drug) $107.38
- BENLYSTA (Biological) $100.77
- Parsabiv (Drug) $100.08
- LUPKYNIS (Drug) $89.38
- FARXIGA (Drug) $69.69
- Velphoro (Drug) $61.07
- JARDIANCE (Drug) $58.80
- Auryxia (Drug) $56.45
- KRYSTEXXA (Biological) $48.48
- Renal - PD (Device) $47.45
- PURIFIED CORTROPHIN GEL (Drug) $42.95
- Inpefa (Drug) $42.16
- AURYXIA (Drug) $36.15
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Arlington
Dr. Israel Hartman, M.d, M.D
Specialist — Payments: $944,018
Specialist $944,018
Dr. Gerard Engh, M.d, M.D
Specialist — Payments: $215,702
Specialist $215,702
Dr. Corey Wallach, Md, MD
Specialist — Payments: $115,045
Specialist $115,045
Bhasker Mehta, Md, MD
Specialist — Payments: $39,798
Specialist $39,798
Dr. Robert Christie, M.d, M.D
Specialist — Payments: $17,207
Specialist $17,207
Dr. Patricia Rodriguez, M.d, M.D
Specialist — Payments: $11,339
Specialist $11,339